Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CNS 2a”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02560753
What this trial is testing

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
T3D Therapeutics, Inc. 36
Post-approval studies (Phase 4)Looking for participantsNCT05357612
What this trial is testing

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Who this might be right for
Neurodegenerative DiseasesParkinson DiseaseParkinson Disease Psychosis
Vanderbilt University Medical Center 75
Testing effectiveness (Phase 2)Looking for participantsNCT06297863
What this trial is testing

Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke

Who this might be right for
Acute Ischemic Stroke
University of Milano Bicocca 118
Testing effectiveness (Phase 2)Study completedNCT01196871
What this trial is testing

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

Who this might be right for
Fabry Disease
Amicus Therapeutics 20
Testing effectiveness (Phase 2)Study completedNCT01767129
What this trial is testing

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Who this might be right for
DyskinesiaParkinson's Disease
Avanir Pharmaceuticals 14
Testing effectiveness (Phase 2)Study completedNCT03608371
What this trial is testing

BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations

Who this might be right for
Parkinson DiseaseMotor Disorder
BlackThorn Therapeutics, Inc. 24
Testing effectiveness (Phase 2)Study completedNCT01199640
What this trial is testing

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Millennium Pharmaceuticals, Inc. 50
Testing effectiveness (Phase 2)Looking for participantsNCT07477639
What this trial is testing

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Who this might be right for
Primary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis (SPMS)Multiple Sclerosis+2 more
Tr1X, Inc. 39
Not applicableWithdrawnNCT03163485
What this trial is testing

Hybrid Device DIALYTRODE for Multimodal Neuro-monitoring of Patients With Brain Injury and Status Epilepticus

Who this might be right for
EpilepsyBrain Injuries
University of Erlangen-Nürnberg Medical School
Testing effectiveness (Phase 2)Study completedNCT04993755
What this trial is testing

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Who this might be right for
Amyotrophic Lateral SclerosisFrontotemporal Dementia
Transposon Therapeutics, Inc. 42
Testing effectiveness (Phase 2)WithdrawnNCT05200104
What this trial is testing

Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

Who this might be right for
ALD (Adrenoleukodystrophy)
Poxel SA
Testing effectiveness (Phase 2)Study completedNCT02244541
What this trial is testing

Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Anavex Life Sciences Corp. 32
Testing effectiveness (Phase 2)Looking for participantsNCT07005180
What this trial is testing

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Who this might be right for
Parkinson Disease
Hillhurst Biopharmaceuticals, Inc. 36
Testing effectiveness (Phase 2)Study completedNCT03027388
What this trial is testing

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Who this might be right for
Astrocytoma, Grades II, III and IVGlioblastoma MultiformeGiant Cell Glioblastoma+2 more
National Cancer Institute (NCI) 7
Testing effectiveness (Phase 2)Looking for participantsNCT05629559
What this trial is testing

4D-310 in Adults With Fabry Disease and Cardiac Involvement

Who this might be right for
Fabry Disease
4D Molecular Therapeutics 18
Testing effectiveness (Phase 2)Study completedNCT06329141
What this trial is testing

Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

Who this might be right for
Parkinson Disease
Glaceum 99
Testing effectiveness (Phase 2)Looking for participantsNCT06596291
What this trial is testing

Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

Who this might be right for
Neurogenic Detrusor OveractivitySpinal Cord Injuries
Cyllene Therapeutics 16
Testing effectiveness (Phase 2)UnknownNCT03625401
What this trial is testing

Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

Who this might be right for
Alzheimer Disease, Early Onset
Zhejiang Hisun Pharmaceutical Co. Ltd. 55
Testing effectiveness (Phase 2)Ended earlyNCT03225846
What this trial is testing

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Who this might be right for
Huntington's Disease
Wave Life Sciences USA, Inc. 88
Testing effectiveness (Phase 2)Study completedNCT01943305
What this trial is testing

The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans

Who this might be right for
Yellow FeverEncephalitis, Japanese
Singapore General Hospital 84
Next Page